Psychiatric treatment conducted via telemedicine versus in-person consultations in mood, anxiety and personality disorders: a protocol for a systematic review and meta-analysis

Ali Abbas Shaker 1,2, Stephen F Austin 1,3, John Aasted Sørensen 4, Ole Jakob Storebø 1,3, Erik Simonsen 1,2

ABSTRACT

Introduction Major advancements in technology have led to considerations how telemedicine (TM) and other technology platforms can be meaningfully integrated in treatment for psychiatric disorders. The COVID-19 pandemic has placed a further focus on use of TM in psychiatry. Despite the widespread use of TM, little is known about its effect compared with traditional in-person (IP) consultation. The objective of this systematic review is to examine if individual psychiatric outpatient interventions for adults using TM are comparable to IP in terms of (1) psychopathology outcomes, (2) levels of patient satisfaction, (3) working alliance and (4) dropout rate from treatment.

Methods and analysis This review will only include randomised controlled trials for adult participants with mood disorders, anxiety or personality disorders. The primary outcome is psychopathology, and secondary outcomes include patient satisfaction, treatment alliance and dropout rate. Systematic searches were conducted in MEDLINE, APA PsycINFO, Embase, Web of Science and CINAHL. The inverse-variance method will be used to conduct the meta-analysis. Effect sizes will be calculated as standardised mean difference (Hedges’ g) for the primary outcome, mean difference for patient satisfaction and working alliance, and risk ratio for the dropout rate. Effect sizes will be supplemented with 95% CI. We will calculate the F statistic to quantify heterogeneity and Chi-square statistic (χ²) to test for heterogeneity for the primary outcome. Potential clinical and methodological heterogeneity moderators will be assessed in subgroup and sensitivity analysis. The risk of bias will be assessed by Cochrane Risk of Bias Tool V.2, and confidence in cumulative evidence will be assessed by Grading of Recommendations Assessment, Development and Evaluation.

Ethics and dissemination No ethical approval is required for this systematic review protocol. Data sets will be deposited in the Zenodo repository. The findings of this study will be published in a peer-review scientific journal.

PROSPERO registration number CRD42021256357.

STRENGTHS AND LIMITATIONS OF THIS STUDY

⇒ This review will include randomised controlled trials to compare individual psychiatric treatment using telemedicine (TM) or in-person (IP) for people with mood, anxiety or personality disorders.

⇒ Validated and standardised measures will be used to assess psychopathology, patient satisfaction (Client Satisfaction Questionnaire-8) and working alliance (Working Alliance Inventory) across all the studies.

⇒ This systematic review will calculate and compare dropout rates between TM and IP treatment formats.

⇒ An outcome that has not previously been examined in a systematic review.

⇒ The stringent eligibility criteria regarding study design, participants, interventions and outcome measures will result in some studies being excluded.

INTRODUCTION

Telemedicine (TM) is, according to the WHO, interpreted as ‘healing at a distance’ that enables remotely delivered treatment while the patient and clinician are in different physical locations. Various names have been suggested and used interchangeably in the scientific literature to describe TM. Telehealth, telepsychiatry, video consultation, video conferencing, telemental health and teleconsultation, for example, are commonly used. TM is the broader term and covers synchronous (video, telephone) and asynchronous (‘store and forward’, ie, emails, SMS) technologies.

Experimentation with TM in medical settings first began in the 1950s. These studies were based on a simple two-way closed-circuit television and TM was used for treatment and education purposes. Advances in technology and increasing access to the internet mean that TM can now be quickly accessed using a smartphone or other digital devices.
Furthermore, the COVID-19 pandemic has led to the accelerated use of digital solutions in healthcare systems in many countries.\textsuperscript{7,8} Currently, there are a number of large ongoing trials comparing TM to in-person (IP) in populations of depression, anxiety, obsessive–compulsive disorder and perinatal women.\textsuperscript{10-12}

The use of TM in mental health services has several potential advantages such as making psychiatric services more accessible and flexible, reducing the cost of transport and time, reducing stigma, promoting patient autonomy and providing an opportunity for people with mental health difficulties to engage with services if they find it challenging to attend IP consultations.\textsuperscript{13,14}

There are also some potential disadvantages of TM, which include concerns about data security, technical obstacles, questions regarding the efficacy of interventions grounded in TM, which patient groups TM is most suitable for, concerns about establishing good working alliances, maintaining treatment engagement and the allocation of resources of trained clinicians.\textsuperscript{15,16} Different populations (eg, geriatric, suicidal or perinatal) can also experience a range of barriers and challenges using TM such as issues of privacy and safety, difficulty learning new technologies or the provision of care for acute mental health problems.\textsuperscript{17-19}

Over the last two decades, several systematic reviews have compared TM with IP within psychiatry.\textsuperscript{20,21} These systematic reviews indicate that TM for psychiatric outpatients is equivalent to IP consultations regarding efficacy (psychopathology, patient satisfaction and working alliance). Unfortunately, the majority of these reviews have usually been descriptive in nature and included trials of varying quality. Furthermore, many of the randomised controlled trials (RCTs) included in these reviews have been underpowered. Currently, there is a lack of quantitative analyses to determine the efficacy of psychiatric treatment provided by TM compared with IP formats.

Three meta-analyses conducted by Drago et al, Batastini et al and Giovanetti et al have examined outcomes comparing TM to IP treatment.\textsuperscript{22-24} Drago et al examined a wide range of interventions within psychiatry but excluded psychotherapeutic interventions. They found that TM was not inferior to IP across a range of mental health outcomes. Batastini et al carried out a large review of TM and IP for a broad range of psychotherapeutic interventions within mental health and they found no significant differences in outcomes between the two treatment formats. Batastini et al’s review included a range of study designs (randomised and non-randomised trials) and different treatment formats (individual and group) across a broad range of mental health related outcomes (symptoms, hospitalisation, relapse, medication compliance). Giovanetti et al conducted a systematic review and meta-analysis to examine the treatment effect for patients with depressive symptoms. Their meta-analysis included 11 RCT studies that directly compared individual psychotherapy through TM with IP and they found no significant differences in outcomes between the two treatment formats. Results from the three reviews conducted indicate that treatment using TM is comparable to IP treatment, although the three research groups also acknowledge a number of limitations with their respective reviews. They recommend that further trials and reviews were necessary and highlight the need for more rigorous study designs, inclusion of a broader range of psychiatric disorders, clearly defined interventions and detailed diagnostic descriptions to develop the evidence base when comparing TM and IP interventions.

Satisfaction outcomes in studies comparing TM to IP in psychiatric outpatients have been assessed in a single meta-analysis by Hyler et al.\textsuperscript{25} This review concluded that there were no differences in levels of patient satisfaction between TM and IP modalities although the authors noted that only a few studies used standardised satisfaction instruments. A number of studies applied ad hoc or untested satisfaction instruments, where the reliability or validity was not reported. It is essential to use standardised and empirically evaluated measures to allow meaningful comparisons between different studies.\textsuperscript{26}

Working alliance was assessed in meta-analysis conducted by Norwood et al that concluded that alliance in TM treatment was inferior to IP treatment.\textsuperscript{27} This finding contrasts with other systematic reviews that suggest that alliance in individual treatment using TM was equal or better than IP treatment.\textsuperscript{21,28,29}

Currently, there is no meta-analysis on dropout rates in treatment using TM compared and IP making it a research area that needs to be addressed.

Based on the current research examining interventions using TM compared with IP consultations, there is a need to conduct a meta-analysis covering a range of psychiatric disorders and focusing on multiple clinical outcomes. This meta-analysis will build on previous research and address some of the current limitations in the literature by conducting a systematic review including studies with rigorous study design (only RCT’s), defined clinical interventions (individual treatment), specific psychiatric populations (diagnoses of anxiety, depression or personality disorder) using standardised assessments for psychopathology, working alliance and treatment satisfaction.

The specific objective of this systematic review is to examine if individual psychiatric outpatient interventions for adults conducted using TM are comparable to IP in terms of (1) psychopathology outcomes, (2) levels of patient satisfaction, (3) working alliance and (4) dropout from treatment.

**METHODS AND ANALYSIS**

This protocol will be conducted according to the Preferred Reporting Items for Systematic Reviews and Meta-analysis Protocol (PRISMA-P).\textsuperscript{30} The PRISMA-P checklist can be found in the online supplemental file 1. The review has been registered in the PROSPERO International Prospective Register of Systematic Reviews (Registration number PRISMA-P-2021-060690).
Trials involving populations that primarily treating different psychotherapy (treatments) approaches in group therapy. Participant <18 years. Non-delivered sessions/consultations in outpatient settings.

**Eligibility criteria**
Eligibility criteria will be based and restricted on the type of study, population, intervention, comparator and outcomes of the studies.

**Types of studies**
Randomised controlled trials.

**Types of participants**
Participants are (1) adults (>18 years), (2) receiving individual psychiatric ambulant treatment and (3) diagnosed with mood disorders, anxiety or personality disorders according to both the American Psychiatric Association’s Diagnostic and Statistical Manual of Mental Disorders III, IV and V and the WHO’s International Statistical Classification of Diseases 9 or 10. Participants with comorbid diagnoses will also be included apart from those diagnoses covered in the exclusion criteria.

**Types of intervention**
Individual treatment through synchronous real-time video delivered sessions/consultations in outpatient settings. Treatment is defined as intervention involving psychotherapy, pharmacological treatment or psychoeducation.

**Types of comparator/control**
Individual treatment IP and same active treatment as the intervention group receives.

**Types of outcomes**
Eligible studies have assessed psychopathology following a mental health service. The secondary outcome of interest includes (a) patient satisfaction, (b) working alliance and (c) dropout rate.

**Exclusion criteria**
- Non-RCT studies.
- Participant ≤18 years.
- Group therapy.
- Different psychotherapy (treatments) approaches in intervention and control group.
- Trials involving populations that primarily treating psychotic disorders, mental retardation, bipolar disorders, alcohol abuse and substance use disorders will be excluded.
- Trials using asynchronous communications systems as an intervention (eg, mails and static website without video function) and telephone (only audio) as the intervention will not be included.

**Information sources and search strategy**
The first step in the systematic review has been a comprehensive search in electronic databases. The database search strings were created in January 2021 by AAS with guidance from the information specialist Trine Kæstel, who has expertise in systematic review searching (psychiatric research unit, Region Zealand). The database search strategy was developed with input from the project team. Search strategies are provided in the online supplemental file 2.

The databases used for the searches are as follow: Medline (PubMed interface, 1986 onwards), APA PsycINFO (OVID interface, 1967 onwards), Embase (OVID interface, 1974 onwards), Web of Science (Clarivate interface, 2001 onwards) and CINAHL (EBSCOhost interface, 1981 onwards).

Medical subject headings and text words related to the search terms ‘psychiatry’ and ‘telemedicine’ were used for developing the search string in MEDLINE. Both search terms—psychiatry and telemedicine—were then combined with [AND]. Specific syntax and subject headings were subsequently adapted individually to the different databases.

No language and date restriction was implemented in the search process. Due to the unmanageable results (>20000 hits) in the preliminary search, Cochrane’s highly sensitive search strategy filters identifying randomised trials has been applied in the final search string. Repeated search will be performed prior to the final analysis to identify further eligible studies. Unpublished studies will not be sought.

The second step in the search strategy will be a manual literature search to identify additional primary studies for the systematic review.

The third step will be scanning the reference lists of included studies or relevant reviews identified in the first and second steps.

**Data management**
Records from the literature search will be exported to the reference manager Endnote V.X9. From Endnote records will be exported to Covidence. Covidence is a web-application tool that facilitates collaboration among the review team members during the study selection and data extraction process. Extracted data in Covidence will be exported to RevMan V.5.4 for data analysis.

**Selection process**
AAS and SFA will be responsible for the selection process. In the first step, the two authors will independently screen the title and abstracts of the records in Covidence to identify potentially eligible records. The second step will be obtaining and screening full-text reports to decide if reports meet eligible criteria. Disagreement through the selection process will be resolved by discussion between the two authors. In case of continued disagreement despite discussion, a third reviewer, OJS will be consulted. The selection process—including exclusion reasons—will be documented in the PRISMA-P flow diagram. Inter-rater reliability will be measured by Cohen’s kappa coefficient (κ) for the (1) title and abstract screening process and (2) full-text review process.
Data collection process
AAS and SFA will be responsible for the data collection process. Data extraction will be carried out through a standardised electronic data extraction form in Covidence. The data extraction form will initially be piloted on some reports, and the reviewers will meet and discuss the form before starting the review. Disagreement through the data collection process will be resolved by discussion between the two authors. In case of continued disagreement despite discussion, a third reviewer (OJS) will be consulted. If we encounter multiple reports of the same study, we will extract data from all reports into a single data collection form in Covidence. Missing data will be obtained by contacting and requesting these data from the study authors.

Data items
We will extract the following data items for each study: (a) study characteristics (authors, author contact details, aim of the study, trial design, location, trial size, sample size calculation, year of publication and country), (b) population characteristics (remote/rural area or urban, country, diagnosis/condition, comorbidity, mean age and gender), (c) intervention/control (internet connection speed, bandwidth, therapy type, number of consultation sessions and duration of consultation) and (d) clinical outcome (assessment tool, psychopathology, satisfaction, alliance, and dropout rate). When reported in the studies, we will collect data from the ‘intention-to-treat’ analysis; otherwise, per-protocol data will be collected. For crossover RCTs, only data before crossover will be used to prevent carryover effects and units of analysis errors.

Outcomes and prioritisation
The primary outcome in this review is psychopathology assessed by clinician or patient-rated scales. As we expect that different assessments tools have been used for measuring the primary outcome, we will prioritise clinician-rated scales and secondary patient-rated scales.

The secondary outcomes in the review will be (a) patient satisfaction, (b) working alliance and (c) dropout rate. Satisfaction must be assessed by Client Satisfaction Questionnaire-8 (CSQ-8), and the working alliance must be assessed by the client Working Alliance Inventory (WAI) in the included studies. The dropout rate is defined as the proportion of individuals who withdrew after being randomised to the total number of participants randomised to a condition.

Risk of bias in individual studies
AAS and SFA will perform the risk-of-bias (quality) assessment in the individual studies. The revised Cochrane Risk of Bias Tool V.2 for randomised trials will be applied. Our primary outcome—psychopathology—will be assessed for risk of bias in each study. The bias domain that will be assessed include (a) bias arising from the randomisation process, (b) bias due to deviations from intended interventions, (c) bias due to missing outcome data, (d) bias in the measurement of the outcome and (e) bias in the selection of the reported result. Overall risks of bias for each study outcome will be marked as: (1) ‘low risk of bias’ if all domains are judged to be low, (2) ‘some concerns’ if at least one domain are judged to raise some concerns but not to be at high risk of bias for any domain and (3) ‘high risk of bias’ if any domain is judged to be at high risk of bias. Disagreement between the mentioned researchers regarding the risk of bias will be resolved through consensus or a third researcher (OJS). Covidence tool will be used to assess the risk of bias.

Data synthesis
The general strategy for our data synthesis is to perform a quantitative synthesis (meta-analysis). A narrative synthesis will be performed if heterogeneity (I²) is substantially high and will include summary tables and descriptions of the findings. I² values will be judged as follows: 0%–40% may represent little heterogeneity, 40%–60% may represent moderate heterogeneity, 60%–90% may represent substantial heterogeneity and 75%–100% represent considerable heterogeneity. Heterogeneity, which is the percentage of variation across studies that is due to heterogeneity rather than chance, will be grouped in (1) clinical, (2) methodological and (3) statistical heterogeneity.

Clinical heterogeneity refers to the variation across studies regarding age, sex, diagnosis, treatment site, and intervention characteristics (duration of intervention, number of interventions and time interval between interventions). Methodological heterogeneity refers to the variability in the risk of bias and outcome measurement tools. Statistical heterogeneity refers to the differences in the intervention effects of each trial being evaluated.

Continuous outcome measures
We will calculate the standardised mean difference (SMD) effect size for the primary outcome using Hedges’ g formula. Because we intend to use different assessments tools to calculate the effect size for the primary outcome in each study, SMD will be statistically suitable for this. Forest plot will be used for presenting effect sizes and overall effect size. A 95% CI will supplement the calculated effect sizes. Furthermore, we will calculate the I² statistic to quantify heterogeneity and Chi-square statistic (χ²) to test for heterogeneity (p≤0.1 significance level).

For the secondary outcomes—satisfaction and working alliance—we will calculate mean difference effect size
as we have restricted these secondary outcomes to be assessed by a standardised tool (CSQ-8 and WAI). Therefore, standardising is not needed to calculate the effect size across the studies. Beyond this, the same statistical approach for the primary outcome already described will be applied to the secondary outcomes satisfaction and working alliance.

We intend to combine ‘end of treatment’ scores (post intervention) and ‘change score’ data (changes from baseline) to calculate the estimated overall effect size for both primary and secondary outcomes. This is a valid approach.34 If the change score is not reported or cannot be calculated, postintervention data will be used as the second choice.

Dichotomous outcome measures
We will calculate the risk ratio effect size and its 95% CI for the secondary outcome (dropout rate). Forest plot will be used to present effect sizes and overall effect size and supplemented with I² and χ² statistics. We define dropout as the number of participants not completing scheduled treatment courses, that is, the difference in the number of participants who started the first treatment session (baseline) and completed the treatment course (post-treatment).

Additional primary outcome analyses (investigating heterogeneity)
For the primary outcome, a subgroup analysis (a) for different patient groups will be performed based on participant diagnosis as specified in the eligibility criteria, (b) sex, (c) ages, (d) length of treatment course/ programme, (e) therapy type, (f) settings (remote / rural area or urban) and (g) vulnerable populations (eg, perinatal, ethnically/racially diverse and geriatric populations).

A sensitivity analysis will be performed to determine the robustness of the meta-analysis and will include: 1. Removing low-quality studies and repeating the meta-analysis. 2. Testing for any possible difference between ‘end-of-treatment’ scores and ‘change scores’. 3. Testing for whether the findings are sensitive to random effects or fixed effects models. 4. Assessing the effect of the year of publication; a meta-regression will be performed, and a p value for the regression will be calculated (p≤0.05 significance level). The rationality for this meta-regression is to analyse if the technological or therapeutic evolution affects the primary outcome.

Meta bias
Publication bias will be assessed and will be done by visually assessing a funnel plot supplied by Egger’s test.34 37

Confidence in cumulative evidence
We will use the Grading of Recommendations Assessment, Development and Evaluation approach as recommended by Cochrane Collaboration to assess the confidence of the body of evidence.34

Patient and public involvement
No patients are involved.

ETHICS AND DISSEMINATION
No ethical approval is required for this systematic review protocol. Data sets will be deposited in the Zenodo repository. The findings of this study will be published in a peer-review scientific journal.

Contributors AAS is the guarantor of the protocol and wrote the first draft protocol. ES, SFA, AAS: developed the idea and rationale for the systematic review. OJS: developed the idea for the protocol and provided statistical inputs. JAS: provided technological perspective and insight. All authors revised and approved the final manuscript.

Funding The authors have not declared a specific grant for this research from any funding agency in the public, commercial or not-for-profit sectors.

Competing interests None declared.

Patient and public involvement Patients and/or the public were not involved in the design, or conduct, or reporting, or dissemination plans of this research.

Patient consent for publication Not applicable.

Provenance and peer review Not commissioned; externally peer reviewed.

Supplemental material This content has been supplied by the author(s). It has not been vetted by BMJ Publishing Group Limited (BMJ) and may not have been peer-reviewed. Any opinions or recommendations discussed are solely those of the author(s) and are not endorsed by BMJ. BMJ disclaims all liability and responsibility arising from any reliance placed on the content. Where the content includes any translated material, BMJ does not warrant the accuracy and reliability of the translations (including but not limited to local regulations, clinical guidelines, terminology, drug names and drug dosages), and is not responsible for any error and/or omissions arising from translation and adaptation or otherwise.

Open access This is an open access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is applicable.

ORCID iDs
Ali Abbas Shaker http://orcid.org/0000-0001-9912-5134
Stephen F Austin http://orcid.org/0000-0001-5988-0565
John Aasted Sørensen http://orcid.org/0000-0003-2852-2292
Ole Jakob Storebø http://orcid.org/0000-0003-0204-7745
Erik Simonsen http://orcid.org/0000-0002-6134-2392

REFERENCES
1 World Health Organization. Report on the second global survey on EHealth global Observatory for EHealth Series-Volume 2 telemedicine in member states; 2010.
2 Turvey C, Coleman M, Dennison O, et al. Atlas practice guidelines for video-based online mental health services. Telemed J E Health 2013;19:722–30.
3 Wittsson CL, Benscherot R. Two-way television: helping the medical center reach out. Am J Psychiatry 1972;129:624–7.
4 Pew Research Center. Demographics of Internet and home broadband usage in the United States | Pew research center. Internet/Broadband fact sheet, 2021. Available: https://www.pewresearch.org/internet/fact-sheet/internet-broadband/ [Accessed 26 Aug 2021].
5 Center PR. Demographics of mobile device ownership and adoption in the United States | Pew research center, 2020. Available: https://www.pewresearch.org/internet/fact-sheet/mobile/ [Accessed 26 Aug 2021].
6 Energiyrlesen. Broadband. Available: https://ens.dk/en/our-responsibilities/broadband [Accessed 26 Aug 2021].
7 Bennett CB, Ruggiero CJ, Sever AC, et al. eHealth to redress psychotherapy access barriers both new and old: a review of reviews and meta-analyses. J Psychother Integr 2020;30:188–207.
8 Wright JH, Caudill R. Remote treatment delivery in response to the COVID-19 pandemic. *Psychother Psychosom* 2020;89:130–2.
9 Wells SY, Morland LA, Wilhite ER, et al. Delivering prolonged exposure therapy via videoconferencing during the COVID-19 pandemic: an overview of the research and special considerations for providers. *J Trauma Stress* 2020;33:380–90.
10 Haun MW, Tönnes J, Krisam R, et al. Mental health specialist video consultations versus treatment as usual in patients with depression or anxiety disorders in primary care: study protocol for an individually randomised superiority trial (the PROVIDE-C trial). *Trials* 2021;22:327.
11 Kishimoto T, Kinoshita S, Bun S, et al. Japanese project for telepsychiatry evaluation during COVID-19: treatment comparison trial (J-PROTECT); rationale, design, and methodology. *Contermp Clin Trials* 2021;11:106596.
12 Singla DP, Meltzer-Brody SE, Silver RK, et al. Scaling up maternal mental healthcare by increasing access to treatment (summit) through non-specialist providers and telemedicine: a study protocol for a non-inferiority randomized controlled trial. *Trials* 2021;22.
13 Chakrabarti S. Usefulness of telepsychiatry; a critical evaluation of videoconferencing-based approaches. *World J Psychiatry* 2015;5:286.
14 Hubley S, Lynch SB, Schneck C, et al. Review of key telepsychiatry outcomes. *World J Psychiatry* 2016;6:269.
15 Cowan KE, McKean AJ, Gentry MT, et al. Barriers to use of telepsychiatry: clinicians as gatekeepers. *Mayo Clin Proc* 2019;94:2510–23.
16 Hailey D, Ohinmaa A, Roine R. Limitations in the routine use of telepsychiatry. *J Telemed Telecare* 2009;15:28–31.
17 Single DR, Meltzer-Brody S, Savel K, et al. Scaling up patient-centered psychological treatments for perinatal depression in the wake of a global pandemic. *Front Psychiatry* 2021;12:2657.
18 Greenhalgh T, Wherton J, Shaw S, et al. Video consultations for covid-19. *BMJ* 2020;368:m986.
19 Siegel A, Zuo Y, Moghaddamcharkari N, et al. Barriers, benefits and interventions for improving the delivery of telemental health services during the coronavirus disease 2019 pandemic: a systematic review. *Curr Opin Psychiatry* 2021;34:434–43.
20 Berryhill MB, Halli-Tierney A, Culmer N, et al. Videoconferencing: a systematic review. *Fam Pract* 2019;36:53–63.
21 Simpson SG, Reid CL. Therapeutic alliance in videoconferencing psychotherapy: a review. *Aust J Rural Health* 2014;22:280–99.
22 Drago A, Winding TN, Antypa N. Videoconferencing in psychiatry, a meta-analysis of assessment and treatment. *Eur Psychiatry* 2016;36:29–37.
23 Batastini AB, Paprzycki P, Jones ACT, et al. Are videoconferenced mental and behavioral health services just as good as in-person? A meta-analysis of a fast-growing practice. *Clin Psychol Rev* 2021;33:101944.
24 Giovanetti AK, Punt SEW, Nelson E-L, et al. Teletherapy versus in-person psychotherapy for depression: a meta-analysis of randomized controlled trials. *Telemedicine and e-Health* 2022;28:1077–89.
25 Hyler SE, Gangure DP, Batchelder ST. Can telepsychiatry replace in-person psychiatric assessments? A review and meta-analysis of comparison studies. *CNS Spectr* 2005;10:403–13.
26 Larsen DL, Attkisson GG, Hargreaves WA, et al. Assessment of client/patient satisfaction: development of a general scale. *Eval Program Plann* 1979;2:197–207.
27 Norwood C, Moghaddam NG, Malins S, et al. Working alliance and outcome effectiveness in videoconferencing psychotherapy: a systematic review and noninferiority meta-analysis. *Clin Psychol Psychother* 2018;25:787–808.
28 Backhaus A, Agha Z, Maglione ML, et al. Videoconferencing psychotherapy: a systematic review. *Psychol Serv* 2012;9:111–31.
29 Sunjaya AP, Chris A, Novianti D. Efficacy, patient-doctor relationship, costs and benefits of utilizing telepsychiatry for the management of post-traumatic stress disorder (PTSD); a systematic review. *Trends Psychiatry Psychother* 2020;42:102–10.
30 Shamseer L, Moher D, Clarke M, et al. Preferred reporting items for systematic review and meta-analysis protocols (PRISMA-P) 2015: elaboration and explanation. *BMJ* 2015;349:g7647.
31 The EndNote Team. *Endnote X9* type: 64 bit. Philadelphia, PA: Clarivate Version, 2013.
32 Covidence systematic review software, veritas health innovation, Melbourne, Australia. Available: www.covidence.org
33 The Cochrane Collaboration. Review Manager (RevMan) [Computer program]. Version 5.4; 2020.
34 Higgins JPT, Thomas J, Chandler J, eds. *Cochrane Handbook for Systematic Reviews of Interventions* version 6.2. Cochrane, 2021. www.training.cochrane.org/handbook
35 Horvath AO, Gravetter F, Z工信 G, et al. Meta-analysis methods: a practical guide. *J Clin Psychol* 1989;45:233–33.
36 da Costa BR, Nüesch E, Rutjes AW, et al. Combining follow-up and change data is valid in meta-analyses of continuous outcomes: a meta-epidemiological study. *J Clin Epidemiol* 2013;66:847–55.
Reporting checklist for protocol of a systematic review and meta analysis.

Based on the PRISMA-P guidelines.

**Instructions to authors**

Complete this checklist by entering the page numbers from your manuscript where readers will find each of the items listed below.

Your article may not currently address all the items on the checklist. Please modify your text to include the missing information. If you are certain that an item does not apply, please write "n/a" and provide a short explanation.

Upload your completed checklist as an extra file when you submit to a journal.

In your methods section, say that you used the PRISMA-Preporting guidelines, and cite them as:

Moher D, Shamseer L, Clarke M, Ghersi D, Liberati A, Petticrew M, Shekelle P, Stewart LA. Preferred Reporting Items for Systematic Review and Meta-Analysis Protocols (PRISMA-P) 2015 statement. Syst Rev. 2015;4(1):1.

| Reporting Item | Page Number |
|----------------|-------------|
| Identification | **#1a** Identify the report as a protocol of a systematic review | 1 |
| Update | **#1b** If the protocol is for an update of a previous systematic review, identify as such | "n/a" |
| Registration | **#2** If registered, provide the name of the registry (such as PROSPERO) and registration number | 1, 2, 4 |
| Authors | **#3a** Provide name, institutional affiliation, e-mail address of all protocol authors; provide physical mailing address of corresponding author | 1 |
Contribution #3b Describe contributions of protocol authors and identify the guarantor of the review

Amendments #4 If the protocol represents an amendment of a previously completed or published protocol, identify as such and list changes; otherwise, state plan for documenting important protocol amendments

Support Sources #5a Indicate sources of financial or other support for the review
Sponsor #5b Provide name for the review funder and / or sponsor
Role of sponsor or funder #5c Describe roles of funder(s), sponsor(s), and / or institution(s), if any, in developing the protocol

Introduction Rationale #6 Describe the rationale for the review in the context of what is already known
Objectives #7 Provide an explicit statement of the question(s) the review will address with reference to participants, interventions, comparators, and outcomes (PICO)

Methods Eligibility criteria #8 Specify the study characteristics (such as PICO, study design, setting, time frame) and report characteristics (such as years considered, language, publication status) to be used as criteria for eligibility for the review
Information sources #9 Describe all intended information sources (such as electronic databases, contact with study authors, trial registers or other grey literature sources) with planned dates of coverage
Search strategy #10 Present draft of search strategy to be used for at least one electronic database, including planned limits, such that it could be repeated
| Category                                      | Code   | Description                                                                                                                                                                                                 | Page(s) |
|----------------------------------------------|--------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|---------|
| Study records - data management              | #11a   | Describe the mechanism(s) that will be used to manage records and data throughout the review                                                                                                                | 5, 6    |
| Study records - selection process            | #11b   | State the process that will be used for selecting studies (such as two independent reviewers) through each phase of the review (that is, screening, eligibility and inclusion in meta-analysis) | 6       |
| Study records - data collection process      | #11c   | Describe planned method of extracting data from reports (such as piloting forms, done independently, in duplicate), any processes for obtaining and confirming data from investigators | 6       |
| Data items                                   | #12    | List and define all variables for which data will be sought (such as PICO items, funding sources), any pre-planned data assumptions and simplifications                                                       | 6       |
| Outcomes and prioritization                  | #13    | List and define all outcomes for which data will be sought, including prioritization of main and additional outcomes, with rationale                                                                         | 6       |
| Risk of bias in individual studies           | #14    | Describe anticipated methods for assessing risk of bias of individual studies, including whether this will be done at the outcome or study level, or both; state how this information will be used in data synthesis | 6       |
| Data synthesis                               | #15a   | Describe criteria under which study data will be quantitatively synthesised                                                                                                                                  | 7       |
| Data synthesis                               | #15b   | If data are appropriate for quantitative synthesis, describe planned summary measures, methods of handling data and methods of combining data from studies, including any planned exploration of consistency (such as I², Kendall’s τ) | 7, 8    |
| Data synthesis                               | #15c   | Describe any proposed additional analyses (such as sensitivity or subgroup analyses, meta-regression)                                                                                                | 7, 8    |
| Data synthesis                               | #15d   | If quantitative synthesis is not appropriate, describe the type of summary planned                                                                                                                         | 7       |
| Meta-bias(es)                                | #16    | Specify any planned assessment of meta-bias(es) (such as publication bias across studies, selective reporting within studies)                                                                                | 8       |
Confidence in cumulative evidence

Describe how the strength of the body of evidence will be assessed (such as GRADE)

None The PRISMA-P elaboration and explanation paper is distributed under the terms of the Creative Commons Attribution License CC-BY. This checklist can be completed online using https://www.goodreports.org/, a tool made by the EQUATOR Network in collaboration with Penelope.ai
## Search Strategy for: *PsycInfo*

**OVID interface**

| #  | Searches                                                                 |
|----|--------------------------------------------------------------------------|
| 1  | exp Treatment Effectiveness Evaluation/                                 |
| 2  | exp Treatment Outcomes/                                                 |
| 3  | exp Placebo/                                                             |
| 4  | exp Followup Studies/                                                   |
| 5  | placebo*.mp.                                                            |
| 6  | random*.mp.                                                             |
| 7  | comparative stud*.mp.                                                   |
| 8  | (clinical adj3 trial*).mp.                                              |
| 9  | (research adj3 design).mp.                                              |
| 10 | (evaluat* adj3 stud*).mp.                                               |
| 11 | (clinical adj3 trial*).mp.                                              |
| 12 | (research adj3 design).mp.                                              |
| 13 | (evaluat* adj3 stud*).mp.                                               |
| 14 | (prospectiv* adj3 stud*).mp.                                           |
| 15 | ((singl* or doubl* or trebl* or tripl*) adj3 (blind* or mask*)).mp.     |
| 16 | 1 or 2 or 3 or 4 or 5 or 6 or 7 or 8 or 9 or 10 or 11 or 12 or 13 or 14 or 15 |
| 17 | exp Psychiatry/                                                          |
| 18 | exp Mental Health/                                                       |
| 19 | exp Mental Disorders/                                                    |
| 20 | exp Mental Health Services/                                              |
| 21 | mental health counseling.ab,sh,ti, tw.                                  |
| 22 | mental health consultation.ab, sh, ti, tw.                              |
| 23 | psychiatric consultation.ab,sh,ti, tw.                                  |
| 24 | psychiatric day treatment.ab,sh,ti, tw.                                 |
| 25 | mental health care.ab,sh,ti, tw.                                       |
| 26 | psychiatric home care.ab,sh,ti, tw.                                     |
| 27 | "psychiatric outpatient"*.ab,sh,ti, tw.                                |
| 28 | 17 or 18 or 19 or 20 or 21 or 22 or 23 or 24 or 25 or 26 or 27           |
| 29 | exp Telemedicine/                                                        |
| 30 | exp Telepsychiatry/                                                     |
| 31 | exp Videoconferencing/                                                  |
| 32 | ehealth.ab,sh,ti, tw.                                                   |
| 33 | telecommunication.ab,sh,ti, tw.                                        |
| 34 | telehealth.ab,sh,ti, tw.                                                |
| 35 | telemental.ab,sh,ti, tw.                                                |
| 36 | "telepsychiatr*"*.ab,sh,ti, tw.                                         |
| 37 | "teletherap*"*.ab,sh,ti, tw.                                            |
| 38 | "videoconferenc*"*.ab,sh,ti, tw.                                        |
| 39 | videophone.ab,sh,ti, tw.                                               |
| 40 | 29 or 30 or 31 or 32 or 33 or 34 or 35 or 36 or 37 or 38 or 39           |
| 41 | 28 and 40                                                               |
| 42 | 16 and 41                                                               |

BMJ Publishing Group Limited (BMJ) disclaims all liability and responsibility arising from any reliance
Supplemental material placed on this supplemental material which has been supplied by the author(s)
| Search Strategy for: Embase |
|-----------------------------|
| **OVID interface**          |
| #  | Searches                                                                 |
| 1  | psychiatry/ or cultural psychiatry/ or emergency psychiatry/ or forensic psychiatry/ or gerontopsychiatry/ or liaison psychiatry/ or neuropsychiatry/ or psychosomatics/ or social psychiatry/ or telepsychiatry/ |
| 2  | exp mental health/                                                     |
| 3  | mental disease/ or addiction/ or adjustment disorder/ or anxiety disorder/ or autism/ or behavior disorder/ or dissociative disorder/ or emotional disorder/ or mood disorder/ or neurosis/ or personality disorder/ or psychosis/ or schizophrinia spectrum disorder/ |
| 4  | exp mental health service/                                            |
| 5  | home mental health care/                                               |
| 6  | "psychiatric consultation"".ab,kw,ti,тов.                             |
| 7  | mental health counseling.ab,kw,ti,тов.                                |
| 8  | psychiatric day treatment.ab,kw,ti,тов.                               |
| 9  | mental health care.ab,kw,ti,тов.                                      |
| 10 | psychiatric home care.ab,kw,ti,тов.                                   |
| 11 | psychiatric outpatient.ab,kw,ti,тов.                                  |
| 12 | "psychiatric outpatient"".ab,kw,ti,тов.                               |
| 13 | mental health home care.ab,ао,kw,ti,тов.                             |
| 14 | 1 or 2 or 3 or 4 or 5 or 6 or 7 or 8 or 9 or 10 or 11 or 12 or 13     |
| 15 | telepsychiatry/                                                       |
| 16 | teleconsultation/ or telediagnosis/ or telemonitoring/ or telepsychiatry/ or teleradiotherapy/ or telerhabilitation/ or teletherapy/ |
| 17 | telehealth/                                                          |
| 18 | telecommunication/ or telemedicine/ or teleconsultation/ or telediagnosis/ or telepsychiatry/ or telerhabilitation/ or teletherapy/ |
| 19 | videoconferencing/                                                   |
| 20 | "videoconferenc*".ab,ао,kw,ti,тов.                                   |
| 21 | videophone.ab,ао,kw,ti,тов.                                          |
| 22 | telehealth.ab,ао,kw,ti,тов.                                          |
| 23 | telemental.ab,ао,kw,ti,тов.                                          |
| 24 | ehealth.ab,ао,kw,ti,тов.                                             |
| 25 | "teletherap*".ab,ао,kw,ти,тов.                                       |
| 26 | telecommunication.ab,ао,kw,ti,тов.                                   |
| 27 | 15 or 16 or 17 or 18 or 19 or 20 or 21 or 22 or 23 or 24 or 25 or 26   |
| 28 | 14 and 27                                                            |
| 29 | (Randomized controlled trial/ or Controlled clinical study/ or random$5.тi,аб. or randomization/ or intermethod comparison/ or placebo.ti,аб. or (compare or compared or comparison).ti or (evaluated or evaluate or evaluating or assessed or assess) and (compare or compared or comparing or comparison)).аб. or (open adj label).тi,аб. or ((double or single or doubly or singly) adj (blind or blinded or blindling)).тi,аб. or double blind procedure/ or parallel group$1.ti,аб. or (crossover or cross over).тi,аб. or ((assign$ or match or matched or allocation) adj5 (alternate or group$1 or intervention$1 or patient$1 or subject$1 or participant$1)).тi,аб. or (assigned or allocated).тi,аб. or (controlled adj? (study or design or trial)).тi,аб. or (volunteer or volunteers).тi,аб. or human experiment/ or trial.тi. not (((random$ adj sample$ adj? ("cross section$" or questionnaire$1 or survey$ or database$1)).тi,аб. not comparative study/ or controlled study/ or random? ed controlled тi,аб. or randomly assigned.тi,аб.)) or (Cross-sectional study/ not (randomized controlled trial/ or controlled clinical study/ or controlled study/ or random? ed controlled тi,аб. or control group$1.тi,аб.)) or (((case adj control$) and random$) not random? ed controlled.тi,аб. or (Systematic review not (trial or study)).тi. or (nonrandom$ not random$).тi,аб. or "Random fieldS".тi,аб. or (random cluster adj? sample$).тi,аб. or ((review.аб. and review.пт.)) not trial.тi. or ("we searched".аб. and (review.тi. or review.пт.) or "update review".аб. or (databases adj4 searched).аб. or (rat or rats or mouse or mice or swine or porcine or murine or sheep or lambs or pigs or piglets or rabbit or rabbits or cat or cats or dog or dogs or cattle or bovine or monkey or monkeys or trout or marmoset$1).тi. and animal experiment/) or (Animal experiment/ not (human experiment/ or human$))) |
| 30 | 28 and 29                                                            |
### Search Strategy for: Medline
**Pubmed Interface**

**Query**

```
(((trial [ti]) OR (randomly [tiab]) OR (clinical trials as topic [mesh: noexp])) OR (placebo [tiab]) OR (randomized [tiab]))
OR (controlled clinical trial [pt]) OR (randomized controlled trial [pt])) NOT (animals [mh] NOT humans [mh]))
AND ("Psychiatry"[MeSH Terms] OR "Mental Disorders"[MeSH Terms] OR "Mental Health Services"[MeSH Terms] OR "Mental Health"[MeSH Terms] OR (mental health counseling)[Title/Abstract] OR mental health consultation)[Title/Abstract] OR psychiatric consultation*)[Title/Abstract] OR psychiatric day treatment)[Title/Abstract] OR mental health care)[Title/Abstract] OR psychiatric home care)[Title/Abstract] OR psychiatric outpatient*)[Title/Abstract] OR "community mental health"[Title/Abstract])
AND (Telemedicine)[MeSH Terms] OR Videoconferencing)[MeSH Terms] OR Remote Consultation)[MeSH Terms] OR (e-health)[Title/Abstract] OR telecare)[Title/Abstract] OR teleconsultation)[Title/Abstract] OR telehome)[Title/Abstract] OR telemedic*)[Title/Abstract] OR telepsychiatr*)[Title/Abstract] OR telemedical)[Title/Abstract] OR televideo)[Title/Abstract] OR telehealth)[Title/Abstract] OR "telemedical"[Title/Abstract] OR "telepsychiatr"[Title/Abstract] OR "telemedic"[Title/Abstract] OR "teleconsultation"[Title/Abstract] OR "telehome"[Title/Abstract] OR "telehealth"[Title/Abstract] OR "teleconference"[Title/Abstract] OR "telemedicine"[Title/Abstract] OR "teletherapy"[Title/Abstract])
```

### Search Strategy for: Web Of Science
**Clarivate interface**

| #  | Searches                                                                 |
|----|-------------------------------------------------------------------------|
| 1  | (Psychiatr* OR (mental NEAR (health OR disorder* OR ill*)) ) OR (counseling NEAR psychology) OR (mental NEAR (counseling OR consultation*)) OR psychiatric consultation* OR psychiatric day treatment OR psychiatric home care OR "mental health service") |
| 2  | (e-health OR telecare OR teleconsultation* OR telehome OR telemedic* OR telepsych* OR telemedical* OR televideo* OR videoconference* OR videophone OR telehealth OR ehealth OR "video conferencing" OR Telecommunication* OR teletherap* OR teleconference*) |
| 3  | 2 AND #1                                                               |
| 4  | TS=(randomised OR randomized OR randomisation OR randomisation OR placebo* OR (random* AND (allocat* OR assign*))) OR (blind* AND (single OR double OR treble OR triple)) |
| 5  | #4 AND #3                                                              |
| #  | Searches                                                                 |
|----|--------------------------------------------------------------------------|
| S35| S31 AND S34 Expanders - Apply equivalent subjects                        |
| S34| S33 NOT S32 Expanders - Apply equivalent subjects                        |
| S33| S32 OR S35 OR S34 OR S35 OR S36 OR S37 OR S38 OR S39 OR S40 OR S41 OR S42 OR S43 OR S44 OR S45 OR S46 Expanders - Apply equivalent subjects |
| S32| S50 NOT S51 Expanders - Apply equivalent subjects                        |
| S31| MH (human) Expanders - Apply equivalent subjects                         |
| S30| S47 OR S48 OR S49 Expanders - Apply equivalent subjects                  |
| S49| TI (animal model*) Expanders - Apply equivalent subjects                 |
| S48| MH (animal studies) Expanders - Apply equivalent subjects               |
| S47| MH animals+ Expanders - Apply equivalent subjects                        |
| S46| AB (cluster W3 RCT) Expanders - Apply equivalent subjects                |
| S45| MH (crossover design) OR MH (comparative studies) Expanders - Apply equivalent subjects |
| S44| AB (control W5 group) Expanders - Apply equivalent subjects              |
| S43| PT (randomized controlled trial) Expanders - Apply equivalent subjects   |
| S42| MH (placebos) Expanders - Apply equivalent subjects                     |
| S41| MH (sample size) AND AB (assigned OR allocated OR control) Expanders - Apply equivalent subjects |
| S40| TI (trial) Expanders - Apply equivalent subjects                         |
| S39| AB (random*) Expanders - Apply equivalent subjects                      |
| S38| TI (randomised OR randomized) Expanders - Apply equivalent subjects      |
| S37| MH cluster sample Expanders - Apply equivalent subjects                 |
| S36| MH pretest-posttest design Expanders - Apply equivalent subjects        |
| S35| MH random assignment Expanders - Apply equivalent subjects              |
| S34| MH single-blind study Expanders - Apply equivalent subjects             |
| S33| MH double-blind studies Expanders - Apply equivalent subjects           |
| S32| MH randomized controlled trials Expanders - Apply equivalent subjects   |
| S31| S29 AND S30 Expanders - Apply equivalent subjects                       |
| S30| S12 OR S13 OR S14 OR S15 OR S16 OR S17 OR S18 OR S19 OR S20 OR S21 OR S22 OR S23 OR S24 OR S25 OR S26 OR S27 OR S28 Expanders - Apply equivalent subjects |
| S29| S1 OR S2 OR S3 OR S4 OR S5 OR S6 OR S7 OR S8 OR S9 OR S10 OR S11 Expanders - Apply equivalent subjects |
| S28| AB teleconference OR TI teleconference Expanders - Apply equivalent subjects |
| S27| AB teletherapy OR TI teletherapy Expanders - Apply equivalent subjects   |
| S26| AB telmental health OR TI telmental health Expanders - Apply equivalent subjects |
| S25| AB videophone OR TI videophone Expanders - Apply equivalent subjects    |
| S24| AB videoconference OR TI videoconference Expanders - Apply equivalent subjects |
| S23| AB televideo OR TI televideo Expanders - Apply equivalent subjects       |
| S22| AB telemedical OR TI telemedical Expanders - Apply equivalent subjects   |
| S21| AB telemental OR TI telemental Expanders - Apply equivalent subjects      |
| S20| AB telemedical OR TI telemental Expanders - Apply equivalent subjects    |
| S19| AB telehome OR TI telehome Expanders - Apply equivalent subjects         |
| S18| AB telecare OR TI telecare Expanders - Apply equivalent subjects         |
| S17| AB ehealth OR TI ehealth Expanders - Apply equivalent subjects           |
| S16| AB e-health OR TI e-health Expanders - Apply equivalent subjects         |
| S15| (MH "Telepsychiatry") OR (MH "Telehabilitation") Expanders - Apply equivalent subjects |
| S14| (MH "Telemedicine") OR (MH "Telenursing") Expanders - Apply equivalent subjects |
| S13| (MH "Remote Consultation") Expanders - Apply equivalent subjects        |
| S12| (MH "Teleconferencing") OR (MH "Telepsychiatry") OR (MH "Telenursing") OR (MH "Telenursing") OR (MH "Telehealth") Expanders - Apply equivalent subjects |
| S11| AB psychiatric day treatment OR TI psychiatric day treatment Expanders   |
| S10| AB mental health consultation OR TI mental health consultation Expanders - Apply equivalent subjects |
| S9 | AB psychiatric consultation OR TI psychiatric consultation Expanders - Apply equivalent subjects |
| S8 | AB counseling psychology OR TI counseling psychology Expanders - Apply equivalent subjects |
| S7 | AB mental health counseling OR TI mental health counseling Expanders - Apply equivalent subjects |
| S6 | (MH "Psychiatric Home Care") Expanders - Apply equivalent subjects      |
| S5 | (MH "Community Mental Health Services") Expanders - Apply equivalent subjects |
| S4 | (MH "Psychiatric Patients") OR (MH "Psychiatric Units") OR (MH "Hospitals, Psychiatric") Expanders - Apply equivalent subjects |
| S3 | (MH "Mental Disorders") OR (MH "Psychiatric Units") OR (MH "Hospitals, Psychiatric") Expanders - Apply equivalent subjects |
| S2 | (MH "Mental Health Services") Expanders - Apply equivalent subjects     |
| S1 | (MH "Psychiatry") Expanders - Apply equivalent subjects                 |
References for RCT filters applied in the search strategies:

Pupmed, Embase and Cinahl[1]
Web of science[2]
PsycInfo [3]

[1] W. L. Lefebvre C, Glanville J, Briscoe S, Littlewood A, Marshall C, Metzendorf M-I, Noel-Storr A, Rader T, Shokran F, Thomas J, “4.S1 Technical Supplement to Chapter 4: Searching for and selecting studies | Cochrane Training,” 2021. https://training.cochrane.org/handbook/current/chapter-04-technical-supplement-searching-and-selecting-studies (accessed Aug. 29, 2021).

[2] “Searching for studies | Cochrane Ear, Nose and Throat.” https://ent.cochrane.org/resources/searching-studies (accessed Aug. 29, 2021).

[3] E. Mccaughan, K. Parahoo, I. Hueter, and L. Northouse, “Online support groups for women with breast cancer,” Cochrane Database Syst. Rev., vol. 2015, no. 4, Apr. 2015, doi: 10.1002/14651858.CD011652/EPDF/FULL.